New clinical trial data reveals significant cardiovascular protection, potentially redefining obesity treatment as preventive cardiology.
Novo Nordisk’s latest trial of semaglutide (Wegovy) has upended assumptions about obesity management. Beyond weight loss, participants experienced a 28% reduction in major cardiovascular events—heart attack, stroke, or cardiac death—compared to placebo. Published in The Lancet, the findings may shift clinical guidelines toward prescribing GLP-1 drugs for heart protection even in non-diabetic patients.
Cardiologists call the data “paradigm-shifting.” Weight loss alone cannot explain the benefits; semaglutide appears to improve endothelial function and inflammation markers directly. As insurers weigh coverage expansion, demand is expected to surge. However, concerns persist over supply shortages and long-term adherence.
With obesity affecting 42% of U.S. adults, the ability to merge metabolic and cardiac therapy into one intervention could reshape preventive medicine—and redefine how healthcare systems quantify value.